Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
934 results
  • Ischemic Colitis in Association with Sevelamer Crystals. [Case Reports]
  • IJIndian J Nephrol 2019 May-Jun; 29(3):191-193
  • Keri KC, Veitla V, Samji NS
  • Sevelamer is an important drug used to lower serum phosphate levels in advanced kidney disease and in patients on dialysis. This drug is generally well tolerated but some patients report mild gastroi…
  • Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients? [Journal Article]
  • DDrugs 2019; 79(8):855-862
  • Lenglet A, Fabresse N, … Massy ZA
  • CONCLUSIONS: In contrast to sevelamer, nicotinamide did not reduce circulating levels of low-molecular-weight uremic toxins other than phosphate, and neither agent reduced circulating uremic toxins of high-molecular-weight or protein-bound toxins. Sevelamer, but not nicotinamide, reduced serum endotoxin levels. Despite no change in serum C-reactive protein, the endotoxin-lowering effect of sevelamer may help to attenuate the inflammatory status of patients with chronic kidney disease.
  • Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. [Journal Article]
  • AJAm J Kidney Dis 2019 Apr 23
  • Ruggiero B, Trillini M, … ANSWER Study Organization
  • CONCLUSIONS: Short treatment duration, lower pretreatment proteinuria than expected.3-month sevelamer treatment did not reduce proteinuria in patients with CKD on maximal RAS blockade. Amelioration of inflammation and dyslipidemia with sevelamer treatment raises the possibility that it may confer benefit in patients with CKD beyond reduction of proteinuria.
New Search Next